|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2002-9-9
|
|
pubmed:abstractText |
In the absence of a cure for multiple myeloma (MM) with standard-dose therapy, any strategy that can be expected to increase tumor reduction and to extend survival duration is likely to be of clinical relevance. The primary end-point of the present study was to investigate whether the alternating combination of vincristine-doxorubicin-dexamethasone (VAD) and melphalan-prednisone (MP) or vincristine-mitoxantrone-dexamethasone (VND) and MP could improve the clinical outcome of MM patients thus treated in comparison with those receiving MP alone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
pubmed-author:BaccaraniMicheleM,
pubmed-author:BenniMonicaM,
pubmed-author:CavoMicheleM,
pubmed-author:CelliniClaudiaC,
pubmed-author:FiacchiniMauroM,
pubmed-author:GozzettiAlessandroA,
pubmed-author:RonconiSoniaS,
pubmed-author:TosiPatriziaP,
pubmed-author:TuraSanteS,
pubmed-author:Writing Committee of the "Bologna 90" Clinical Trial,
pubmed-author:ZamagniElenaE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
87
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
934-42
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12217805-Adult,
pubmed-meshheading:12217805-Age Factors,
pubmed-meshheading:12217805-Aged,
pubmed-meshheading:12217805-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12217805-Doxorubicin,
pubmed-meshheading:12217805-Etoposide,
pubmed-meshheading:12217805-Female,
pubmed-meshheading:12217805-Humans,
pubmed-meshheading:12217805-Male,
pubmed-meshheading:12217805-Melphalan,
pubmed-meshheading:12217805-Middle Aged,
pubmed-meshheading:12217805-Mitoxantrone,
pubmed-meshheading:12217805-Multiple Myeloma,
pubmed-meshheading:12217805-Prednisone,
pubmed-meshheading:12217805-Randomized Controlled Trials as Topic,
pubmed-meshheading:12217805-Salvage Therapy,
pubmed-meshheading:12217805-Survival Rate,
pubmed-meshheading:12217805-Time Factors,
pubmed-meshheading:12217805-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
|
|
pubmed:affiliation |
Institute of Hematology and Medical Oncology Seràgnoli, via Massarenti 9, 40138 Bologna, Italy. mcavo@med.unibo.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
